HYSINGLA ER

2. Frequency of HYSINGLA ER dosing
5. Do this by 25% to the calculated oral hydrocodone dose in opioid tolerant patients
6. _____ properties that are expected to deter intranasal and intravenous abuse
8. Clinical trials conducted in opioid ____ and opioid _______
9. This pain type was evaluated in the HYSINGLA ER pivotal efficacy trial (12-Week Study)
11. Abuse deterrent technology
12. Starting dose in opioid naive
13. This is a differentiating characteristic of Hysingla ER
14. Percentage of HYSINGLA ER patients who completed the double-blind, 12-week treatment
16. Initiation of CYP3A4 _______ can result in fatal overdose of hydrocodone from Hysingla ER
18. 1:1 conversion from any other __________ product
19. Mean terminal half-life at steady state

1. Median TMax values on both Day 1 and Day 5
3. HYSINGLA ER is indicated for use when these treatment options are inadequate
4. ____ _____ the continued need for the use of opioid analgesics
7. _____ _____ strengths allows for individualized treatment
10. Hysingla ER contains none of this analgesic
15. Recommended frequency for adjusting the HYSINGLA ER dose as needed is every ____ __ ____ days
17. Hysingla ER provides 24-hour delivery of